The US Food and Drug Administration (FDA) has approved the novel calcimimetic etelcalcetide (Parsabiv, Amgen) for the treatment of secondary hyperparathyroidism in adults on hemodialysis.

Secondary hyperparathyroidism is a complex endocrine condition characterized by excess circulating parathyroid hormone (PTH) resulting from an underlying condition, most commonly chronic kidney ...

Please provide your email address to receive an email when new articles are posted on . A lower parathyroid hormone target treatment method was linked with reduced adjusted hazard of death. The ...

The appraisal committee reviewed the data available on the clinical and cost effectiveness of etelcalcetide, having considered evidence on the nature of secondary hyperparathyroidism and the value ...

Please provide your email address to receive an email when new articles are posted on . Adults who underwent Roux-en-Y gastric bypass who were also vitamin D deficient had an increased risk for ...

Secondary hyperparathyroidism commonly develops in patients with chronic kidney disease (CKD) in response to high phosphate, low calcium and low 1α,25-dihydroxyvitamin D 3 (calcitriol) levels. High ...

This section presents medications that are known to potentially lead to 'Hyperparathyroidism secondary' as a side effect. It's important to note that mild side effects are quite common with ...

Gastritis Predisposes Diabetes Patients to Metformin’s GI Effects If validated, new study findings may be used to develop a disease-specific patient-reported outcome measure that will inform SHPT ...

SECONDARY hyperparathyroidism associated with chronic renal disease may simulate primary hyper-parathyroidism with secondary renal impairment in virtually every particular. An exception is the brown ...

Some people with hyperparathyroidism may notice weight gain or weight loss. These changes may occur due to factors like underlying medical conditions or appetite changes. Hyperparathyroidism is ...

However, despite suggestions that such secondarily stimulated hyperparathyroidism may become autonomous 12–14 convincing data regarding such a possibility are not available, owing to the great excess ...